Future studies should explore the underlying mechanisms of CRP and lymphocyte fluctuations in CAD, evaluate their potential as therapeutic targets, and develop tailored intervention strategies to enhance the prevention and management of cardiovascular diseases. The gene discussed is CRP; the disease is cardiovascular disorder.